← All Adicet Bio, INC filings

Adicet Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ACET
Adicet Bio, INC
10-K/A: Adicet Bio Files Amended 10-K for Fiscal Year 2025
Adicet Bio, Inc. has filed an amendment to its 2025 annual report (10-K/A) to update disclosures regarding its internal controls and procedures.
NASDAQ
ACET
Adicet Bio, INC
10-K: Adicet Bio Advances Autoimmune Therapies, Secures Funding
Adicet Bio reports positive preliminary Phase 1 results for prula-cel in autoimmune diseases, plans pivotal trials, and secures financing while facing substantial losses.
NASDAQ
ACET
Adicet Bio, INC
10-K: Adicet Bio Reports Full Year 2024 Results, Highlights Progress in Autoimmune and Cancer Programs
Adicet Bio advances clinical development of ADI-001 in autoimmune diseases and ADI-270 in renal cell carcinoma while reporting a net loss of $117.1 million for the year ended December 31, 2024.
NASDAQ
ACET
Adicet Bio, INC
10-K: Adicet Bio Reports Full Year 2023 Results, Outlines 2024 Clinical and Pipeline Milestones
Adicet Bio's 2023 10-K filing details progress in clinical trials for ADI-001 and ADI-270, along with plans for further development in autoimmune diseases and cancer.